Iktos and Chemspeed Technologies (a Bruker company) recently announced a collaboration to bridge the gap between AI-driven molecule design and physical chemical synthesis.
As a strategic investor in Iktos, we are pleased to see their orchestration technology integrated with Chemspeed’s world-class robotics. This synergy directly addresses a primary bottleneck in drug discovery by creating a seamless “molecules-to-robot” pipeline. By automating the decision workflow, from retrosynthesis to final synthesis scheduling, the platform allows chemists to execute complex, diverse synthesis campaigns with unprecedented speed and minimal manual intervention.
This partnership is a significant step toward making autonomous chemistry workflows accessible to research teams globally, further solidifying Iktos’ role in the digital transformation of the lab.
Read the full announcement and learn more.